^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PM1080

    i
    Associations
    News

    Trials

    Company:
    BioNTech, Jiangsu Hansoh Pharma
    Drug class:
    EGFR inhibitor, c-MET inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase Ib Trial of HS-20117 in Combination with Other Drugs in Advanced Solid Tumors (NCT06621563)
    Phase 1
    Hansoh BioMedical R&D Company
    Not yet recruiting
    Last update posted :
    10/01/2024
    Initiation :
    12/01/2024
    Primary completion :
    03/30/2026
    Completion :
    12/01/2026
    BRAF
    |
    cisplatin • carboplatin • 5-fluorouracil • GSK5764227 • PM1080
    A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors (NCT05940116)
    Phase 1
    Hansoh BioMedical R&D Company
    Not yet recruiting
    Last update posted :
    07/12/2023
    Initiation :
    07/20/2023
    Primary completion :
    07/30/2025
    Completion :
    07/30/2027
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    PM1080